9 December 2020 - Valeo Pharma announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin biosimilars.

In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defence tool in the fight against Covid-19.

Read Valeo Pharma press release